Medical Uncertainty and Practice Variation Get Personal: What Should I Do about Hormone Replacement Therapy?
Authors: Jennifer Daley
Journal: Annals of Internal Medicine (1999)

Editorials6 April 1999Medical Uncertainty and Practice Variation Get Personal: What Should I Do about Hormone Replacement Therapy?Jennifer Daley, MDJennifer Daley, MDBeth Israel Deaconess Medical Center; Boston, MA 02215 (Daley)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-130-7-199904060-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Dr. Daley, what should I do about hormone replacement therapy?” As a clinician-teacher for the first 15 years of my career, my practice was devoted mostly to women who chose me to care for them. I saw the ravages of osteoporosis, breast cancer, hyperlipidemia, cardiovascular disease, Alzheimer disease, and depression in my patients who were over 55 years of age, and tried to help. My patients under 40 years of age exercised regularly; took vitamins; read voraciously about women's health; and were determined to improve their sense of well-being, increase their longevity, and “take control” of their health. With women ...References1. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130:545-53. LinkGoogle Scholar2. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736-46. CrossrefMedlineGoogle Scholar3. McClung M, Clemmesen B, Daifoitis A, Gilchrist NL, Eisman J, Weinstein RS, et al . Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med. 1998;128:253-61. LinkGoogle Scholar4. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992;305:556-61. CrossrefMedlineGoogle Scholar5. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al . Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-61. CrossrefMedlineGoogle Scholar6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al . Randomized trial of estrogen plus progestin for secondary prevention of coronary artery disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13. CrossrefMedlineGoogle Scholar7. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects of cognitive function and dementia. JAMA. 1998;279:688-95. CrossrefMedlineGoogle Scholar8. Eddy DM. Variations in physician practice: the role of uncertainty. Health Aff (Millwood). 1984;3:74-89. CrossrefMedlineGoogle Scholar9. Wennberg JE. On patient need, equity, supplier-induced demand, and the need to assess the outcome of common medical practices. Med Care. 1985;23:512-20. CrossrefMedlineGoogle Scholar10. Mort EA. Medical decision-making in the face of scientific uncertainty: hormone replacement therapy as an example. J Fam Pract. 1996;42:147-51. MedlineGoogle Scholar11. Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ, Ross EM, et al . Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277:1140-7. CrossrefMedlineGoogle Scholar12. Greendale GA, Carlson KJ, Schiff I. Estrogen and progestin therapy to prevent osteoporosis: attitudes and practices of general internists and gynecologists. J Gen Intern Med. 1990;5:464-9. CrossrefMedlineGoogle Scholar13. Stafford RS, Saglam D, Causino N, Blumenthal D. Low rate of hormone replacement in visits to United States primary care physicians. Am J Obstet Gynecol. 1997;177:381-7. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Beth Israel Deaconess Medical Center; Boston, MA 02215 (Daley)Corresponding Author: Jennifer Daley, MD, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUse of Hormone Replacement Therapy by Postmenopausal Women in the United States Nancy L. Keating , Paul D. Cleary , Alice S. Rossi , Alan M. Zaslavsky , and John Z. Ayanian Medical Uncertainty and Practice Variation Jack Beaird Metrics Cited ByEvidence-Based Medicine, Postmenopausal Hormone Therapy, and the Women's Health InitiativeUncertainty in Clinical MedicineCultural and Socioeconomic Determinants of Antibiotic UseFactors associated with intention to use hormone replacement therapy among Thai middle-aged womenAn Informatics Infrastructure Is Essential for Evidence-based PracticeHormone Replacement Therapy: Primary and Secondary PreventionHormone replacement therapyMedical Uncertainty and Practice VariationJack Beaird, MDEthnic differences in hormone replacement prescribing patternsPatient-Identified Needs for Hormone Replacement Therapy Counseling: A Qualitative StudyMaureen T. Connelly, MD, MPH, Nancy Ferrari, AB, Nicole Hagen, BA, MHS, and Thomas S. Inui, ScM, MD 6 April 1999Volume 130, Issue 7Page: 602-604KeywordsAlzheimer diseaseBreast cancerCardiovascular diseasesCardiovascular therapyDecision makingEpidemiologyHormone replacement therapyMenopauseObstetrics and gynecologyOsteoporosis Issue Published: 6 April 1999 CopyrightCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...